Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT06739850

Identification of Risk Phenotypes for Sarcopenia Using DXA WBC, Anthropometric and MA Among Young Adults

Identification of Risk Phenotypes for Sarcopenia Using DXA Whole Body Composition, Anthropometric and Muskuloskeltal Analysis Among Young Adults

Status
Active Not Recruiting
Phase
Study type
Observational
Enrollment
221 (actual)
Sponsor
Superior University · Academic / Other
Sex
All
Age
15 Years – 35 Years
Healthy volunteers
Not accepted

Summary

This cross-sectional study aims to identify risk phenotypes for sarcopenia among young adults using Dual-energy X-ray Absorptiometry (DXA) for whole-body composition analysis, along with anthropometric and musculoskeletal assessments. Sarcopenia, characterized by the loss of muscle mass and strength, is a growing concern, particularly among the aging population.

Detailed description

However, early identification in young adults can allow for preventive strategies to improve long-term health outcomes. This study, involving 221 participants aged 15 to 35, focuses on assessing the correlation between DXA-derived body composition, musculoskeletal fitness, and anthropometric measurements with sarcopenia risk. Primary outcome measures include DXA imaging and dynamometry for body composition and strength evaluation, while secondary outcomes focus on detailed anthropometric and musculoskeletal analyses. By addressing early risk factors in younger populations, this research hopes to enhance understanding of sarcopenia's development and support early intervention strategies. Data collection is conducted at the Center of Nuclear Medicine in Lahore, Pakistan.

Conditions

Interventions

TypeNameDescription
COMBINATION_PRODUCTIdentification of Risk Phenotypes of SarcopeniaSarcopenia is a condition characterized by progressive loss of skeletal muscle mass, strength, and function, often associated with aging. Traditionally, it is studied in older populations, but your focus is on identifying its early manifestations in young adults, potentially offering a window for prevention.

Timeline

Start date
2024-02-28
Primary completion
2024-05-31
Completion
2025-03-01
First posted
2024-12-18
Last updated
2024-12-18

Locations

1 site across 1 country: Pakistan

Source: ClinicalTrials.gov record NCT06739850. Inclusion in this directory is not an endorsement.